iSTAR Medical

iSTAR Medical SA, headquartered in Wavre, Belgium, is a clinical stage medical technology company focused on the development of novel ophthalmic implants for glaucoma. 

Glaucoma is the second leading cause of adult blindness globally. Micro-invasive glaucoma surgery (MIGS) is the most promising and fastest-growing therapeutic option in the treatment of glaucoma. 

iSTAR has exclusive rights to the STAR biomaterial from the University of Washington in Seattle (USA) for ophthalmic use. This provides the foundation for the development of MINIject, which is designed to be a best in class MIGS device. The fast-growing glaucoma drainage device market is expected to reach $1.84bn worldwide by 2025 (Market Scope, 2020). 

iSTAR Medical’s management team and board have a successful track record in end-to-end product development, with proven clinical, regulatory and market access capabilities. The company is backed by specialised institutional and private investors.